CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Dapagliflozin 10Mg Tabdrug
Likely dose
Dapagliflozin 10Mg Tabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05335629
NCT05335629N/ACompleted
CompareCT.gov

Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients

Ain Shams University·interventional·Posted Apr 19, 2022·Updated Feb 1, 2024

In Brief

A clinical study evaluating Dapagliflozin 10Mg Tab for Myocardial Infarction and 2 related conditions. Completed, enrolled 54 participants across 1 site.

Detailed Summary

A prospective, randomized, controlled study will be conducted at Clinical Cardioglogy department, Ain Shams University Hospitals, assessing the efficacy and tolerability of SGLT2 inhibitors (dapagliflozin) addition on the clinical outcome and cardiac remodeling markers of post myocardial infarction (MI) diabetic patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 19, 2022
Enrollment StartJun 1, 2022
Primary CompletionOct 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.2 years ago

Interventions

Dapagliflozin 10Mg Tabdrug

Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose